<p>貝克頓，迪金森（NYSE: BDX）正在準備於 2026 年 2 月 9 日（星期一）公佈其季度財報。以下是投資者在發佈前應瞭解的簡要概述。</p>
<p>分析師預計貝克頓，迪金森的每股收益（EPS）為 2.82 美元。</p>
<p>投資者對貝克頓，迪金森的公告充滿期待，希望聽到超出預期的消息以及對下個季度的積極指引。</p>
<p>新投資者應理解，雖然盈利表現很重要，但市場反應往往受到指引的驅動。</p>
<h3>盈利歷史快照</h3>
<p>該公司在上個季度的每股收益超出預期 0.05 美元，導致次日股價上漲 0.25%。</p>
<p>以下是貝克頓，迪金森的過去表現及其價格變化：</p>
<table>
<thead>
<tr>
<th><strong>季度</strong></th>
<th align="right"><strong>2025 年第四季度</strong></th>
<th align="right"><strong>2025 年第三季度</strong></th>
<th align="right"><strong>2025 年第二季度</strong></th>
<th align="right"><strong>2025 年第一季度</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS 預估</strong></td>
<td align="right">3.91</td>
<td align="right">3.41</td>
<td align="right">3.28</td>
<td align="right">2.99</td>
</tr>
<tr>
<td><strong>EPS 實際</strong></td>
<td align="right">3.96</td>
<td align="right">3.68</td>
<td align="right">3.35</td>
<td align="right">3.43</td>
</tr>
<tr>
<td><strong>價格變化 %</strong></td>
<td align="right">0.00</td>
<td align="right">3.00</td>
<td align="right">0.00</td>
<td align="right">-7.00</td>
</tr>
</tbody>
</table>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770386452_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="eps graph" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770386452_0.png"/></p>
<h3>股票表現</h3>
<p>截至 2 月 4 日，貝克頓，迪金森的股價為 206.51 美元。在過去 52 周內，股價下跌了 10.04%。鑑於這些回報通常是負面的，長期股東在此次財報發佈前可能會感到有些不滿。</p>
<h3>分析師對貝克頓，迪金森的看法</h3>
<p>對於投資者來説，掌握市場情緒和行業預期至關重要。本文分析了關於貝克頓，迪金森的最新見解。</p>
<p>貝克頓，迪金森獲得了分析師的 5 個評級，普遍評級為中性。平均一年期目標價為 209.4 美元，表明潛在上漲 0.74%。</p>
<h3>行業同行評級比較</h3>
<p>以下是貝克頓，迪金森、IDEXX Laboratories、Edwards Lifesciences 和 ResMed 這三家行業知名公司的分析師評級和平均一年期目標價的比較，提供了它們相對錶現預期和市場定位的見解。</p>
<ul>
<li>分析師目前對 IDEXX Laboratories 的表現持樂觀態度，平均一年期目標價為 795.0 美元，表明潛在上漲 282.45%。</li>
<li>分析師目前對 Edwards Lifesciences 的表現持買入態度，平均一年期目標價為 97.35 美元，表明潛在下跌 53.17%。</li>
<li>分析師目前對 ResMed 的表現持中性態度，平均一年期目標價為 286.29 美元，表明潛在上漲 37.73%。</li>
</ul>
<h3>同行分析總結</h3>
<p>在同行分析總結中，展示了 IDEXX Laboratories、Edwards Lifesciences 和 ResMed 的關鍵指標，揭示了它們在行業中的地位，並提供了對其市場位置和相對錶現的有價值見解。</p>
<table>
<thead>
<tr>
<th>公司</th>
<th>共識</th>
<th>收入增長</th>
<th>毛利潤</th>
<th>股本回報率</th>
</tr>
</thead>
<tbody>
<tr>
<td>貝克頓，迪金森</td>
<td>中性</td>
<td>8.35%</td>
<td>28 億美元</td>
<td>1.94%</td>
</tr>
<tr>
<td>IDEXX Laboratories</td>
<td>超越市場</td>
<td>-1.33%</td>
<td>6.8335 億美元</td>
<td>15.68%</td>
</tr>
<tr>
<td>Edwards Lifesciences</td>
<td>買入</td>
<td>14.67%</td>
<td>12.1 億美元</td>
<td>2.81%</td>
</tr>
<tr>
<td>ResMed</td>
<td>中性</td>
<td>10.98%</td>
<td>8.7872 億美元</td>
<td>6.31%</td>
</tr>
</tbody>
</table>
<p>關鍵要點：</p>
<p>貝克頓，迪金森在同行中收入增長排名中等。與其他公司相比，其毛利潤和股本回報率最低。</p>
<h3>揭示貝克頓，迪金森背後的故事</h3>
<p>貝克頓，迪金森是全球最大的醫療外科產品製造和分銷商，產品包括針頭、注射器和鋭器處置單元。該公司還製造預填充設備、診斷儀器和試劑，以及流式細胞儀和細胞成像系統。BD Medical 幾乎佔總業務的一半，而 BD Life Sciences（2024 年收入的 26%）和 BD Interventional（25%）佔據其餘部分。國際收入佔公司業務的 43%。</p>
<h3>理解數字：貝克頓，迪金森的財務狀況</h3>
<p><strong>市值分析：</strong> 超過行業基準，該公司的市值強調了其顯著規模，表明其強大的市場存在。</p>
<p><strong>收入增長：</strong> 在過去的 3 個月中，貝克頓，迪金森表現積極，截至 2025 年 9 月 30 日，其收入增長率為 <strong>8.35%</strong>。這反映了公司頂線收益的顯著增長。與競爭對手相比，該公司面臨困難，增長率低於醫療保健行業同行的平均水平。</p>
<p><strong>淨利潤率：</strong> 貝克頓，迪金森的淨利潤率令人印象深刻，超過行業平均水平。淨利潤率為 <strong>8.37%</strong>，表明公司盈利能力強，成本管理有效。</p>
<p><strong>股本回報率（ROE）：</strong> 該公司的 ROE 低於行業基準，表明在有效利用股本方面可能存在困難。ROE 為 <strong>1.94%</strong>，公司可能需要解決為股東創造滿意回報的挑戰。</p>
<p><strong>資產回報率（ROA）：</strong> 貝克頓，迪金森的 ROA 低於行業標準，表明在有效利用資產方面可能存在困難。ROA 為 <strong>0.89%</strong>，公司可能面臨從其資產中提供滿意回報的挑戰。</p>
<p><strong>債務管理：</strong> 貝克頓，迪金森的債務與股本比率為 <strong>0.76</strong>，低於平均水平，採用謹慎的財務策略，表明其在債務管理方面採取了平衡的方法。</p>
<p>要跟蹤貝克頓，迪金森的所有財報發佈，請訪問我們網站上的財報日曆。</p>
<p><em>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</em></p>

標普健康醫療設備 ETF - SPDR

碧迪醫療

美國醫藥設備 ETF - iShares

<p>碧迪醫療（Becton, Dickinson，紐約證券交易所代碼：BDX）將於 2026 年 2 月 9 日公佈季度財報，分析師預計每股收益（EPS）為 2.82 美元。該公司的分析師共識評級為中性，目標股價為 209.4 美元，顯示出 0.74% 的潛在上漲空間。碧迪醫療的股價在過去一年下跌了 10.04%，在同行中其收入增長排名中等，增長率為 8.35%。該公司擁有強勁的淨利潤率為 8.37%，但與行業基準相比，股本回報率和資產回報率較低</p>

<p>Becton, Dickinson (NYSE: BDX) is gearing up to announce its quarterly earnings on Monday, 2026-02-09. Here's a quick overview of what investors should know before the release.</p>
<div class="lb-trans"><p>貝克頓，迪金森（NYSE: BDX）正在準備於 2026 年 2 月 9 日（星期一）公佈其季度財報。以下是投資者在發佈前應瞭解的簡要概述。</p>
</div><p>Analysts are estimating that Becton, Dickinson will report an <strong>earnings per share</strong> (EPS) of $2.82.</p>
<div class="lb-trans"><p>分析師預計貝克頓，迪金森的每股收益（EPS）為 2.82 美元。</p>
</div><p>Anticipation surrounds Becton, Dickinson's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<div class="lb-trans"><p>投資者對貝克頓，迪金森的公告充滿期待，希望聽到超出預期的消息以及對下個季度的積極指引。</p>
</div><p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<div class="lb-trans"><p>新投資者應理解，雖然盈利表現很重要，但市場反應往往受到指引的驅動。</p>
</div><h3>Earnings History Snapshot</h3>
<div class="lb-trans"><h3>盈利歷史快照</h3>
</div><p>The company's EPS beat by $0.05 in the last quarter, leading to a 0.25% increase in the share price on the following day.</p>
<div class="lb-trans"><p>該公司在上個季度的每股收益超出預期 0.05 美元，導致次日股價上漲 0.25%。</p>
</div><p>Here's a look at Becton, Dickinson's past performance and the resulting price change:</p>
<div class="lb-trans"><p>以下是貝克頓，迪金森的過去表現及其價格變化：</p>
</div><table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th align="right"><strong>Q4 2025</strong></th>
<th align="right"><strong>Q3 2025</strong></th>
<th align="right"><strong>Q2 2025</strong></th>
<th align="right"><strong>Q1 2025</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td align="right">3.91</td>
<td align="right">3.41</td>
<td align="right">3.28</td>
<td align="right">2.99</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td align="right">3.96</td>
<td align="right">3.68</td>
<td align="right">3.35</td>
<td align="right">3.43</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td align="right">0.00</td>
<td align="right">3.00</td>
<td align="right">0.00</td>
<td align="right">-7.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th><strong>季度</strong></th>
<th align="right"><strong>2025 年第四季度</strong></th>
<th align="right"><strong>2025 年第三季度</strong></th>
<th align="right"><strong>2025 年第二季度</strong></th>
<th align="right"><strong>2025 年第一季度</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS 預估</strong></td>
<td align="right">3.91</td>
<td align="right">3.41</td>
<td align="right">3.28</td>
<td align="right">2.99</td>
</tr>
<tr>
<td><strong>EPS 實際</strong></td>
<td align="right">3.96</td>
<td align="right">3.68</td>
<td align="right">3.35</td>
<td align="right">3.43</td>
</tr>
<tr>
<td><strong>價格變化 %</strong></td>
<td align="right">0.00</td>
<td align="right">3.00</td>
<td align="right">0.00</td>
<td align="right">-7.00</td>
</tr>
</tbody>
</table>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1770386452_0.png" alt="eps graph" original-src="https://www.benzinga.com/files/images/story/2026/1770386452_0.png"/></p>
<h3>Stock Performance</h3>
<div class="lb-trans"><h3>股票表現</h3>
</div><p>Shares of Becton, Dickinson were trading at $206.51 as of February 04. Over the last 52-week period, shares are down 10.04%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release.</p>
<div class="lb-trans"><p>截至 2 月 4 日，貝克頓，迪金森的股價為 206.51 美元。在過去 52 周內，股價下跌了 10.04%。鑑於這些回報通常是負面的，長期股東在此次財報發佈前可能會感到有些不滿。</p>
</div><h3>Analysts' Perspectives on Becton, Dickinson</h3>
<div class="lb-trans"><h3>分析師對貝克頓，迪金森的看法</h3>
</div><p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Becton, Dickinson.</p>
<div class="lb-trans"><p>對於投資者來説，掌握市場情緒和行業預期至關重要。本文分析了關於貝克頓，迪金森的最新見解。</p>
</div><p>Becton, Dickinson has received a total of 5 ratings from analysts, with the consensus rating as Neutral. With an average one-year price target of $209.4, the consensus suggests a potential 0.74% upside.</p>
<div class="lb-trans"><p>貝克頓，迪金森獲得了分析師的 5 個評級，普遍評級為中性。平均一年期目標價為 209.4 美元，表明潛在上漲 0.74%。</p>
</div><h3>Comparing Ratings Among Industry Peers</h3>
<div class="lb-trans"><h3>行業同行評級比較</h3>
</div><p>The below comparison of the analyst ratings and average 1-year price targets of IDEXX Laboratories, Edwards Lifesciences and ResMed, three prominent players in the industry, gives insights for their relative performance expectations and market positioning.</p>
<div class="lb-trans"><p>以下是貝克頓，迪金森、IDEXX Laboratories、Edwards Lifesciences 和 ResMed 這三家行業知名公司的分析師評級和平均一年期目標價的比較，提供了它們相對錶現預期和市場定位的見解。</p>
</div><ul>
<li>Analysts currently favor an Outperform trajectory for IDEXX Laboratories, with an average 1-year price target of $795.0, suggesting a potential 282.45% upside.</li>
<li>Analysts currently favor an Buy trajectory for Edwards Lifesciences, with an average 1-year price target of $97.35, suggesting a potential 53.17% downside.</li>
<li>Analysts currently favor an Neutral trajectory for ResMed, with an average 1-year price target of $286.29, suggesting a potential 37.73% upside.</li>
</ul>
<div class="lb-trans"><ul>
<li>分析師目前對 IDEXX Laboratories 的表現持樂觀態度，平均一年期目標價為 795.0 美元，表明潛在上漲 282.45%。</li>
<li>分析師目前對 Edwards Lifesciences 的表現持買入態度，平均一年期目標價為 97.35 美元，表明潛在下跌 53.17%。</li>
<li>分析師目前對 ResMed 的表現持中性態度，平均一年期目標價為 286.29 美元，表明潛在上漲 37.73%。</li>
</ul>
</div><h3>Analysis Summary for Peers</h3>
<div class="lb-trans"><h3>同行分析總結</h3>
</div><p>Within the peer analysis summary, vital metrics for IDEXX Laboratories, Edwards Lifesciences and ResMed are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<div class="lb-trans"><p>在同行分析總結中，展示了 IDEXX Laboratories、Edwards Lifesciences 和 ResMed 的關鍵指標，揭示了它們在行業中的地位，並提供了對其市場位置和相對錶現的有價值見解。</p>
</div><table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Becton Dickinson</td>
<td>Neutral</td>
<td>8.35%</td>
<td>$2.80B</td>
<td>1.94%</td>
</tr>
<tr>
<td>IDEXX Laboratories</td>
<td>Outperform</td>
<td>-1.33%</td>
<td>$683.35M</td>
<td>15.68%</td>
</tr>
<tr>
<td>Edwards Lifesciences</td>
<td>Buy</td>
<td>14.67%</td>
<td>$1.21B</td>
<td>2.81%</td>
</tr>
<tr>
<td>ResMed</td>
<td>Neutral</td>
<td>10.98%</td>
<td>$878.72M</td>
<td>6.31%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>公司</th>
<th>共識</th>
<th>收入增長</th>
<th>毛利潤</th>
<th>股本回報率</th>
</tr>
</thead>
<tbody>
<tr>
<td>貝克頓，迪金森</td>
<td>中性</td>
<td>8.35%</td>
<td>28 億美元</td>
<td>1.94%</td>
</tr>
<tr>
<td>IDEXX Laboratories</td>
<td>超越市場</td>
<td>-1.33%</td>
<td>6.8335 億美元</td>
<td>15.68%</td>
</tr>
<tr>
<td>Edwards Lifesciences</td>
<td>買入</td>
<td>14.67%</td>
<td>12.1 億美元</td>
<td>2.81%</td>
</tr>
<tr>
<td>ResMed</td>
<td>中性</td>
<td>10.98%</td>
<td>8.7872 億美元</td>
<td>6.31%</td>
</tr>
</tbody>
</table>
</div><p>Key Takeaway:</p>
<div class="lb-trans"><p>關鍵要點：</p>
</div><p>Becton, Dickinson ranks in the middle for revenue growth among its peers. It has the lowest gross profit and return on equity compared to others.</p>
<div class="lb-trans"><p>貝克頓，迪金森在同行中收入增長排名中等。與其他公司相比，其毛利潤和股本回報率最低。</p>
</div><h3>Unveiling the Story Behind Becton, Dickinson</h3>
<div class="lb-trans"><h3>揭示貝克頓，迪金森背後的故事</h3>
</div><p>Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.</p>
<div class="lb-trans"><p>貝克頓，迪金森是全球最大的醫療外科產品製造和分銷商，產品包括針頭、注射器和鋭器處置單元。該公司還製造預填充設備、診斷儀器和試劑，以及流式細胞儀和細胞成像系統。BD Medical 幾乎佔總業務的一半，而 BD Life Sciences（2024 年收入的 26%）和 BD Interventional（25%）佔據其餘部分。國際收入佔公司業務的 43%。</p>
</div><h3>Understanding the Numbers: Becton, Dickinson's Finances</h3>
<div class="lb-trans"><h3>理解數字：貝克頓，迪金森的財務狀況</h3>
</div><p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 超過行業基準，該公司的市值強調了其顯著規模，表明其強大的市場存在。</p>
</div><p><strong>Revenue Growth:</strong> Over the 3 months period, Becton, Dickinson showcased positive performance, achieving a revenue growth rate of <strong>8.35%</strong> as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<div class="lb-trans"><p><strong>收入增長：</strong> 在過去的 3 個月中，貝克頓，迪金森表現積極，截至 2025 年 9 月 30 日，其收入增長率為 <strong>8.35%</strong>。這反映了公司頂線收益的顯著增長。與競爭對手相比，該公司面臨困難，增長率低於醫療保健行業同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> Becton, Dickinson's net margin is impressive, surpassing industry averages. With a net margin of <strong>8.37%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<div class="lb-trans"><p><strong>淨利潤率：</strong> 貝克頓，迪金森的淨利潤率令人印象深刻，超過行業平均水平。淨利潤率為 <strong>8.37%</strong>，表明公司盈利能力強，成本管理有效。</p>
</div><p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>1.94%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<div class="lb-trans"><p><strong>股本回報率（ROE）：</strong> 該公司的 ROE 低於行業基準，表明在有效利用股本方面可能存在困難。ROE 為 <strong>1.94%</strong>，公司可能需要解決為股東創造滿意回報的挑戰。</p>
</div><p><strong>Return on Assets (ROA):</strong> Becton, Dickinson's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>0.89%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<div class="lb-trans"><p><strong>資產回報率（ROA）：</strong> 貝克頓，迪金森的 ROA 低於行業標準，表明在有效利用資產方面可能存在困難。ROA 為 <strong>0.89%</strong>，公司可能面臨從其資產中提供滿意回報的挑戰。</p>
</div><p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.76</strong>, Becton, Dickinson adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<div class="lb-trans"><p><strong>債務管理：</strong> 貝克頓，迪金森的債務與股本比率為 <strong>0.76</strong>，低於平均水平，採用謹慎的財務策略，表明其在債務管理方面採取了平衡的方法。</p>
</div><p>To track all earnings releases for Becton, Dickinson visit their earnings calendar on our site.</p>
<div class="lb-trans"><p>要跟蹤貝克頓，迪金森的所有財報發佈，請訪問我們網站上的財報日曆。</p>
</div><p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>
<div class="lb-trans"><p><em>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</em></p>
</div>

碧迪醫療即將發佈的財報概覽